Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. - sprookjes - yvandenbroek - TriplyDB

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

http://www.wikidata.org/entity/Q33922982

about

Survival of encapsulated islets: More than a membrane story T Helper Subsets, Peripheral Plasticity, and the Acute Phase Protein, α1-Antitrypsin Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes Expanding the clinical indications for α(1)-antitrypsin therapy Context-Specific and Immune Cell-Dependent Antitumor Activities of α1-Antitrypsin Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injury Characterization of acute renal allograft rejection by proteomic analysis of renal tissue in rat.Saving islets from allograft rejection.Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor The immunoregulation effect of alpha 1-antitrypsin prolong β-cell survival after transplantation Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation.α-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration.Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.Alpha 1 Antitrypsin Inhibits Dendritic Cell Activation and Attenuates Nephritis in a Mouse Model of Lupus.Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival.Human Alpha-1-Antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury.Molecular pathogenesis of emphysema Insulin degradation by acinar cell proteases creates a dysfunctional environment for human islets before/after transplantation: benefits of α-1 antitrypsin treatment Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways Allograft inflammatory factor-1 and its immune regulation.Effect of recombinant α1-antitrypsin Fc-fused (AAT-Fc)protein on the inhibition of inflammatory cytokine production and streptozotocin-induced diabetes.alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.Allogeneic islet transplantation.Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.Challenges and emerging technologies in the immunoisolation of cells and tissues.α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.Ex vivo gene transfer of viral interleukin-10 to BB rat islets: no protection after transplantation to diabetic BB rats.Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice.Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.Exploration of α1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration.alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies.Lung disease associated with alpha1-antitrypsin deficiency.Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent.Immune-modulating effects of alpha-1 antitrypsin.

P2860

Q26751467-6A2BA96C-AA38-48BA-AEF5-880B4A0BEC65 Q26829272-67741988-0D77-4E58-8DDF-EEB5D74A126D Q26858837-A102E28F-E3EC-4A25-BA04-C4BADE666AFF Q26861561-E128133F-C5D8-47E2-8710-62D9D627FF98 Q27000764-C06052E7-AAC2-44C2-BC5D-C0FA03B7FEF0 Q28817846-6737118A-F6E3-4874-95F2-69BE319050A3 Q30436677-FD8B0B5D-7FC5-49A6-A528-6D7F2DBC74A9 Q33908781-67D4876A-5939-4C60-A33F-05C42B46DDDE Q33943978-C267531E-45B5-441D-A6AB-FF19222AECD7 Q34744307-70E95798-7C5C-4F56-9526-4677A003835D Q35130769-8D0A44AE-41EF-4281-BE4D-546A752FF79E Q35145461-E7C524A6-7719-4B16-A6FB-67B22F136DA2 Q35179622-8E9E65C5-F791-49B9-BDA0-889BE5304FE9 Q35286904-86F933D4-9647-4B8C-8F7A-4EED69C17B43 Q35286977-60E1F5B8-3720-4C57-AA27-B336DEADB33E Q35673668-81C709E8-4BDA-4020-A962-63565EF17930 Q36032325-9CFC7ECD-FDC6-4D81-BB92-2F2CFDA187F8 Q36280053-F6DE9EE8-1173-4259-82E2-53EFBB7A46EA Q36290085-DDCA1742-1E7C-40F6-ABB4-E6D900992AC4 Q36407009-C94962EB-ED96-45A1-B2B2-C0F31838AE82 Q36655234-4D9FBE20-F6DC-417B-9E25-804BC6A020E3 Q36675994-315A4F8E-E948-4119-9799-48A377CBE112 Q36799403-598BEEE1-69E5-4B2C-A12B-AA19978C2B1D Q36885672-7FD9FB12-823B-4529-BBFD-703F9D6F76E9 Q36935759-092CEA60-6196-4106-B74A-5D0894A360CD Q36945031-653FF183-77CF-4A89-93D8-63B50D00AD1C Q36981652-54C25DFC-1BB0-4A25-9224-B7B1B3C7D814 Q36999931-B886E88F-0553-4FA2-B90F-CFAC6E3165C6 Q37006047-A34D5545-E0B6-4F07-B6DA-A898EABBCCDE Q37056456-75CA527C-3EC3-49E0-B4A5-4F5FA8D65479 Q37159126-22A18F2D-3309-427E-B0E6-A22C158DF62B Q37173117-A043D311-4984-4959-837D-5621FB8396B3 Q37295677-35753542-8C6A-4432-9A6B-D0E18C256346 Q37311032-BF3498AD-BDBC-4454-B366-3989B502A92F Q37404257-F49A0E3D-1782-4339-8B68-8C41C1AF4D7D Q37427900-5E9417C7-3144-46A7-B6D3-F66204582356 Q37474870-0BBBBF08-0282-4D84-868C-04F1640657FC Q37804626-471288AE-FD0C-426C-800B-CF8FFD7E1038 Q37986292-48C9AC52-4900-45C2-86A7-EB9633CB0CB2 Q38214040-29748D5A-0F37-47AB-B428-807EC60B39AD

P2860

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

http://www.wikidata.org/entity/Q33922982

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@ast

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@en

type

label

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@ast

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@en

prefLabel

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@ast

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@en

P1433

Q33922982-F5BA87D7-33B8-416A-9BB1-8A2DCE614566

P1476

Q33922982-4C03BB09-8562-4AD3-9480-55DD4FA04DFB

P2093

Q33922982-3E28C0DF-2696-4930-A402-1AC2F28DA014

Q33922982-90BD14B8-AB4C-4622-B001-D8DE2009D87F

Q33922982-B443AE4B-F4D9-46DA-B287-456C4B835590

P2860

Q33922982-1C887F1D-2F56-4F0E-89CA-558BF7BE2B41

Q33922982-23F9489D-7829-42A9-832A-B113D1DA4A1F

Q33922982-2630EA01-BFEB-4643-804C-81C26B0CACA4

Q33922982-30628DAC-B493-4064-A04D-A8C25EA701F7

Q33922982-37641F3F-E5B5-4135-920B-F65405E73229

Q33922982-3C37C60B-722C-48DD-9C86-D79B80765660

Q33922982-4447DF42-A2A8-4091-853A-22EFEFAE3D11

Q33922982-4818F1E4-3DDF-4C5D-8E41-2ECA3F3B2EAF

Q33922982-5DF4E627-C9CB-4C3F-B8BB-F336E30D064A

Q33922982-70163585-5C92-4C71-A986-7CDC3EC22830

P304

Q33922982-5B292B17-4527-467A-9F8D-B0726482E385

P31

Q33922982-FC86625C-B74B-4306-83FF-DB6D76D2BCE6

P356

Q33922982-B02931C4-01C8-4EE6-9600-058CE1BB6834

P407

Q33922982-F5F58611-E432-4AFD-8435-13076B957276

P433

Q33922982-C39C5E1E-BD2A-48DF-AE9F-F5534C6B71A3

P478

Q33922982-B6F22AE7-0CF5-4502-AB28-CC827773329E

P50

Q33922982-AFA47CD6-9FE1-4D67-9286-71D3674C88FF

P577

Q33922982-7D403813-EE89-49D2-A049-8BA01D1052DE

P5875

Q33922982-A77F0B1F-C7B4-4CF0-9134-3F6EA028A4E2

P698

Q33922982-2BC984E0-7C51-4F1F-9A83-81B277457D0A

P932

Q33922982-B838E23A-FFA8-471D-9D01-8AE1661E0C34

P356

PNAS.0505579102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.

@en

P2093

Eli C Lewis

http://www.w3.org/2001/XMLSchema#string

Leland Shapiro

http://www.w3.org/2001/XMLSchema#string

Owen J Bowers

http://www.w3.org/2001/XMLSchema#string

P2860

Two distinct cytokines released from a human aminoacyl-tRNA synthetase

Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases

Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release

Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation

Tumor necrosis factor-alpha converting enzyme

Characterization of islet-infiltrating immunocytes after pancreas preservation by two-layer (UW/perfluorochemical) cold storage method.

On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes.

Antigen markers of macrophage differentiation in murine tissues.

Clinical islet transplantation: advances and immunological challenges.

The current situation in human pancreatic islet transplantation: problems and prospects.

P304

12153-12158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0505579102

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Charles A. Dinarello

P577

2005-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7667678

http://www.w3.org/2001/XMLSchema#string

P698

16093309

http://www.w3.org/2001/XMLSchema#string

P932

1189344

http://www.w3.org/2001/XMLSchema#string